Last reviewed · How we verify
Panipenem-Betamipron Mixt (carbenin)
Panipenem-Betamipron Mixt (generic name: carbenin) is a carbenin drug. It is currently in unknown development.
Panipenem-Betamipron Mixt works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death.
Panipenem-Betamipron Mixt is a carbapenem antibiotic marketed by Daiichi Sankyo Co. of Japan, launched in 1993 under the brand name Carbenin.
At a glance
| Generic name | carbenin |
|---|---|
| Drug class | carbenin |
| Therapeutic area | Infectious Disease |
| Phase | unknown |
Mechanism of action
Imagine your body's cells are like buildings, and the bacteria are like construction workers. Panipenem-Betamipron Mixt stops the construction workers from building new walls, which eventually causes the building to collapse and the bacteria to die.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Panipenem-Betamipron Mixt CI brief — competitive landscape report
- Panipenem-Betamipron Mixt updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Panipenem-Betamipron Mixt
What is Panipenem-Betamipron Mixt?
How does Panipenem-Betamipron Mixt work?
What is the generic name of Panipenem-Betamipron Mixt?
What drug class is Panipenem-Betamipron Mixt in?
What development phase is Panipenem-Betamipron Mixt in?
Related
- Drug class: All carbenin drugs
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Infectious Disease
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing